NeoGenomics, Inc. (NASDAQ:NEO) reported a full-year diluted earnings per share (EPS) of -$0.84, missing estimates, but exceeded revenue expectations with full-year revenue of $727 million. In the fourth quarter, NEO achieved an adjusted diluted EPS of $0.06, surpassing the Zacks Consensus Estimate of $0.04, indicating a 50% earnings surprise.
With a negative trailing price-to-earnings (P/E) ratio of approximately -12.5, NEO’s price-to-sales ratio of around 2.06 and a current ratio of 4.26 highlight its market valuation and liquidity strength.
NeoGenomics, Inc. (NASDAQ:NEO) is a prominent player in the medical, biomedical, and genetics industry. The company is known for its comprehensive cancer diagnostic testing services. Despite facing challenges, NEO continues to show resilience in its financial performance. It competes with other companies in the same sector, striving to maintain its position in the market. On February 17, 2026, NEO reported a full-year diluted earnings per share (EPS) of -$0.84, which was below estimates. This indicates a significant deviation from expectations. However, the company managed to exceed revenue forecasts, reporting full-year revenue of $727 million (up 10% from $661 million the prior year). In the fourth quarter, NEO achieved an adjusted diluted EPS of $0.06, surpassing the Zacks Consensus Estimate of $0.04. This represents a 50% earnings surprise, a notable improvement from the adjusted diluted EPS of $0.04 in the same quarter the previous year.
Over the past four quarters, NEO has exceeded consensus adjusted EPS estimates three times, demonstrating its capacity to outperform market expectations. NEO’s revenue for the quarter ending December 2025 was $190 million, exceeding the Zacks Consensus Estimate by approximately 0.9% to 1.1% (based on estimates ranging from $188.14 million to $189.93 million). This is a significant increase from the $172 million reported in the same period the previous year.
The company has surpassed consensus revenue estimates twice in the last four quarters, showcasing its consistent revenue growth. With a negative trailing price-to-earnings (P/E) ratio of approximately -12.5, NEO’s price-to-sales ratio of around 2.06 suggests that the market values its sales at about $2.06 for every dollar of sales. The enterprise value to sales ratio is approximately 2.3, reflecting the company’s total valuation relative to its sales. With a current ratio of 4.26, NEO maintains a strong liquidity position, indicating its ability to cover current liabilities with its assets.
